Literature DB >> 24895782

Lovastatin inhibited the growth of gastric cancer cells.

Yang Cheng-Qian, Wei Xin-Jing, Gao Zhuang-Lei, Zhao Hong-Peng, Xu Songde, Wang Pei-Lin.   

Abstract

BACKGROUND/AIMS: Gastric cancer cells required large amount of cholesterol to grow and proliferate. The objective of this study was to examine whether the growth of gastric cancer cells was inhibited in vivo by using lovastatin, an effective cholesterol-lowing drug.
METHODOLOGY: The mice models for gastric cancer cells MKN45 were divided into two groups, the control and experimental group. Lovastatin was administered orally to the experimental group, while saline given to the control group. We measured the volume and weight of tumors, and calculated RTV (relative tumor volume), T/C (relative added value of tumor) and the inhibition rate. Then the expression levels of PCNA in gastric cancer tissues were examined immunohistochemically.
RESULTS: The volume of tumors in the control and experimental groups was 3.801 +/- 1.078 and 3.325 +/- 0.745, respectively (p > 0.05), while RTV was 49.684 +/- 12.250 and 42.506 +/- 10.515, respectively (p > 0.05). T/C, an indication of antitumor, was 85.55%. The weight of tumors of the mice in control and experimental group was 3.23 +/- 0.43 and 2.65 +/- 0.58, respectively (p < 0.05). The inhibition rate was 20.48%. The PCNA index in the lovastatin group was 32.35 +/- 6.43%, while in the control group was 91.24 +/- 6.59%. The PCNA index of lovastatin group was much lower (P < 0.01).
CONCLUSIONS: Lovastatin inhibited the growth of gastric cancer cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24895782

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Anti-Proliferation Activity of Fucoidan in MKN45 Gastric Cancer Cells and Downregulation of Phosphorylated ASK1, a Cell Cycle-Regulated Kinase.

Authors:  Miwa Yoshimoto; Katsumi Higaki; Eiji Nanba; Masahide Ikeguchi
Journal:  Yonago Acta Med       Date:  2015-03-27       Impact factor: 1.641

Review 2.  Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mingjie Yuan; Shuyi Han; Yanfei Jia; Jiankai Feng; Duanrui Liu; Zhenguo Su; Xiangdong Liu
Journal:  Int J Clin Pract       Date:  2022-05-17       Impact factor: 3.149

3.  Mitochondrial Acetyl-CoA Synthetase 3 is Biosignature of Gastric Cancer Progression.

Authors:  Wei-Chun Chang; Wei-Chung Cheng; Bi-Hua Cheng; Lumin Chen; Li-Jing Ju; Yu-Jer Ou; Long-Bin Jeng; Mei-Due Yang; Yao-Ching Hung; Wen-Lung Ma
Journal:  Cancer Med       Date:  2018-03-01       Impact factor: 4.452

4.  Identification and Verification of Potential Biomarkers in Gastric Cancer By Integrated Bioinformatic Analysis.

Authors:  Chenyu Sun; Yue Chen; Na Hyun Kim; Scott Lowe; Shaodi Ma; Zhen Zhou; Rachel Bentley; Yi-Sheng Chen; Margarita Whitaker Tuason; Wenchao Gu; Chandur Bhan; John Pocholo Whitaker Tuason; Pratikshya Thapa; Ce Cheng; Qin Zhou; Yanzhe Zhu
Journal:  Front Genet       Date:  2022-07-15       Impact factor: 4.772

5.  Effect of pravastatin on the survival of patients with advanced gastric cancer.

Authors:  Luis Bujanda; Araceli Rodríguez-González; Cristina Sarasqueta; Emma Eizaguirre; Elizabeth Hijona; José J G Marín; María J Perugorria; Jesús M Banales; Angel Cosme
Journal:  Oncotarget       Date:  2016-01-26

Review 6.  Aberrant lipid metabolism reprogramming and immune microenvironment for gastric cancer: a literature review.

Authors:  Meng-Ying Cui; Xing Yi; Dan-Xia Zhu; Jun Wu
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.